Outcomes of CAR T-cell therapies after prior treatment with fixed-duration mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Abstract
Background: Mosunetuzumab (Mosun) is a CD20xCD3 bispecific antibody (BsAb) evaluated in patients (pts) with B-cell non-Hodgkin lymphoma (B-NHL) in a Phase I/II clinical trial (NCT02500407). Based on this study, intravenous (IV) Mosun is approved for the treatment of pts with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior lines of systemic therapy. The optimal sequencing of available therapies and whether prior exposure to BsAbs impacts the effectiveness of subsequent CD19-targeted chimeric antigen receptor (CAR) T-cell therapies remain unclear. Limited data suggest that the efficacy of CAR T-cell therapies is preserved in pts with large B-cell lymphoma (LBCL) who received prior BsAbs (Crochet et al. Blood 2024). Here, we present a US multicenter, retrospective, case series to evaluate the outcomes of pts with R/R B-NHL treated with CAR T-cell therapy after Mosun.
Methods: Pts from all dose-escalation and expansion cohorts in a Phase I/II clinical trial (NCT02500407) were included in this analysis. Efficacy and safety outcomes were investigated in pts with R/R B-NHL who received CAR T-cell therapy for the first time following Mosun treatment. Eligible pts were treated with autologous CAR T-cell therapy between December 8, 2015 and August 9, 2021.
Results: At data cut-off (May 13, 2024), 48 pts with R/R B-NHL had received CAR T-cell therapy following Mosun treatment; available data from 22 pts are presented here. Median age was 67 years (range: 52–81) and…
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 12 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.